Early Detection of Heart and Blood Vessel Problems in Adults Aged 18 to 65 With Acute Myeloid Leukemia Undergoing Chemotherapy

What this Trial Is About

Acute myeloid leukemia AML is a disease where immature blood cells grow uncontrollably due to a mutation. This condition is treated with anthracycline antibiotics, which have been used since the 1970s. However, these drugs can harm the heart, causing problems like heart failure and irregular heartbeats. This trial aims to improve early detection of heart and blood vessel problems related to chemotherapy in AML patients by using detailed tests and measurements. Participants will receive chemotherapy containing anthracyclines and cytarabine following a standard regimen. The study compares two groups of AML patients aged 18 to 65, all without signs of heart failure and with normal heart function initially. One group shows a decrease in heart muscle strain during treatment, while the control group does not. Various diagnostic tests, including laser Doppler flowmetry, stress echocardiography, blood tests for heart and vessel markers, and imaging scans, will be performed before and after each chemotherapy course. Participants will undergo multiple assessments such as history taking, body measurements, blood tests, heart imaging, and vessel scans throughout up to 10 months of chemotherapy treatment. The study will measure changes in heart muscle strain, microcirculation, and biochemical markers after each chemotherapy cycle to find early signs of heart and vascular damage. This information will help develop an algorithm for early detection of heart complications in AML patients receiving chemotherapy.

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML